Catarina M Quinzii

List of Publications by Year
in descending order

59	3,274	159585 30	168389 53
papers	citations	h-index	g-index

60	60	60	4472
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) Mutations. American Journal of Human Genetics, 2006, 79, 1125-1129.	6.2	359
2	ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 Deficiency. American Journal of Human Genetics, 2008, 82, 661-672.	6.2	290
3	Human Coenzyme Q10 Deficiency. Neurochemical Research, 2007, 32, 723-727.	3.3	163
4	Coenzyme Q and mitochondrial disease. Developmental Disabilities Research Reviews, 2010, 16, 183-188.	2.9	157
5	Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ ₁₀ deficiency. FASEB Journal, 2008, 22, 1874-1885.	0.5	150
6	Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ ₁₀ deficiency. FASEB Journal, 2010, 24, 3733-3743.	0.5	142
7	Supercompetitor Status of Drosophila Myc Cells Requires p53 as a Fitness Sensor to Reprogram Metabolism and Promote Viability. Cell Metabolism, 2014, 19, 470-483.	16.2	115
8	Emerging therapies for mitochondrial diseases. Essays in Biochemistry, 2018, 62, 467-481.	4.7	113
9	X-Linked Dominant Scapuloperoneal Myopathy Is Due to a Mutation in the Gene Encoding Four-and-a-Half-LIM Protein 1. American Journal of Human Genetics, 2008, 82, 208-213.	6.2	108
10	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. Journal of Clinical Investigation, 2020, 130, 3699-3716.	8.2	104
11	Primary and secondary CoQ₁₀ deficiencies in humans. BioFactors, 2011, 37, 361-365.	5.4	96
12	Treatment of CoQ10 Deficient Fibroblasts with Ubiquinone, CoQ Analogs, and Vitamin C: Time- and Compound-Dependent Effects. PLoS ONE, 2010, 5, e11897.	2.5	92
13	CoQ10 deficiencies and MNGIE: Two treatable mitochondrial disorders. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 625-631.	2.4	83
14	High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ Function InÂVivo. Cell Metabolism, 2014, 19, 539-547.	16.2	82
15	Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Molecular Medicine, 2014, 6, 1016-1027.	6.9	79
16	The clinical heterogeneity of coenzyme Q₁₀ deficiency results from genotypic differences in the Coq9 gene. EMBO Molecular Medicine, 2015, 7, 670-687.	6.9	77
17	Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clinical Cancer Research, 2018, 24, 5392-5406.	7.0	67
18	Multiple System Atrophy and Amyotrophic Lateral Sclerosis in a Family With Hexanucleotide Repeat Expansions inC9orf72. JAMA Neurology, 2014, 71, 771.	9.0	66

#	Article	IF	Citations
19	Tissueâ€specific oxidative stress and loss of mitochondria in CoQâ€deficient Pdss2 mutant mice. FASEB Journal, 2013, 27, 612-621.	0.5	61
20	Coenzyme Q deficiency causes impairment of the sulfide oxidation pathway. EMBO Molecular Medicine, 2017, 9, 96-111.	6.9	61
21	Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 663-672.	1.7	57
22	CoQ10 deficiency diseases in adults. Mitochondrion, 2007, 7, S122-S126.	3.4	55
23	Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy. Stem Cell Reports, 2018, 11, 1185-1198.	4.8	46
24	The Role of Sulfide Oxidation Impairment in the Pathogenesis of Primary CoQ Deficiency. Frontiers in Physiology, 2017, 8, 525.	2.8	41
25	Effects of Inhibiting CoQ10 Biosynthesis with 4-nitrobenzoate in Human Fibroblasts. PLoS ONE, 2012, 7, e30606.	2.5	40
26	Clinical Presentations of Coenzyme Q10 Deficiency Syndrome. Molecular Syndromology, 2014, 5, 141-146.	0.8	38
27	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nature Communications, 2021, 12, 5203.	12.8	38
28	Metabolic Targets of Coenzyme Q10 in Mitochondria. Antioxidants, 2021, 10, 520.	5.1	37
29	CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3708-3722.	3.8	35
30	Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma. Clinical Cancer Research, 2018, 24, 3941-3954.	7.0	35
31	A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. Brain, 2019, 142, 2756-2774.	7.6	35
32	MET Inhibition Elicits PGC1Î±-Dependent Metabolic Reprogramming in Glioblastoma. Cancer Research, 2020, 80, 30-43.	0.9	35
33	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597.	3.8	32
34	Activation of <scp>LXR</scp> Î² inhibits tumor respiration and is synthetically lethal with Bclâ€• <scp>xL</scp> inhibition. EMBO Molecular Medicine, 2019, 11, e10769.	6.9	32
35	Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. Npj Genomic Medicine, 2019, 4, 18.	3.8	29
36	Inefficient thermogenic mitochondrial respiration due to futile proton leak in a mouse model of fragile X syndrome. FASEB Journal, 2020, 34, 7404-7426.	0.5	26

#	Article	IF	Citations
37	Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. Journal of Clinical Investigation, 2021, 131, .	8.2	25
38	Pathomechanisms in Coenzyme Q₁₀-Deficient Human Fibroblasts. Molecular Syndromology, 2014, 5, 163-169.	0.8	23
39	Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway. Human Molecular Genetics, 2015, 24, 4516-4529.	2.9	23
40	Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. Cells, 2020, 9, 1661.	4.1	20
41	Coenzyme Q10 modulates sulfide metabolism and links the mitochondrial respiratory chain to pathways associated to one carbon metabolism. Human Molecular Genetics, 2020, 29, 3296-3311.	2.9	16
42	A Novel SUCLA2 Mutation Presenting as a Complex Childhood Movement Disorder. Journal of Child Neurology, 2017, 32, 246-250.	1.4	15
43	Abnormalities of hydrogen sulfide and glutathione pathways in mitochondrial dysfunction. Journal of Advanced Research, 2021, 27, 79-84.	9.5	11
44	Mutant CHCHD10 causes an extensive metabolic rewiring that precedes OXPHOS dysfunction in a murine model of mitochondrial cardiomyopathy. Cell Reports, 2022, 38, 110475.	6.4	11
45	Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice. Human Molecular Genetics, 2019, 28, 209-219.	2.9	9
46	CoQ10 Deficiency Is Not a Common Finding in GLUT1 Deficiency Syndrome. JIMD Reports, 2015, 29, 47-52.	1.5	7
47	Coenzyme Q10 as a Peripheral Biomarker for Multiple System Atrophy. JAMA Neurology, 2016, 73, 917.	9.0	7
48	Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure. Thorax, 2019, 74, 1099-1101.	5.6	7
49	Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. Scientific Reports, 2018, 8, 7373.	3.3	6
50	Redefining infantile-onset multisystem phenotypes of coenzyme Q10-deficiency in the next-generation sequencing era. , 2020, 4, 22-35.		6
51	Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias. Current Neuropharmacology, 2018, 17, 21-32.	2.9	4
52	Cerebellar Ataxia and Deficiency. , 2013, 1, 1004.		3
53	Mechanisms and Therapeutic Effects of Benzoquinone Ring Analogs in Primary CoQ Deficiencies. Antioxidants, 2022, 11, 665.	5.1	3
54	Metabolic studies of a patient harbouring a novel S487L mutation in the catalytic subunit of AMPK. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1896-1903.	3.8	1

#	Article	IF	Citations
55	Regulatory environment for novel therapeutic development in mitochondrial diseases. Journal of Inherited Metabolic Disease, 2021, 44, 292-300.	3.6	1
56	Coenzyme Q10 Deficiency. , 2019, , 169-182.		0
57	ETMM-04. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA MODEL SYSTEMS. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	0
58	Inefficient Thermogenic Mitochondrial Respiration Due to Futile Proton Leak in a Mouse Model of Fragile X Syndrome. SSRN Electronic Journal, 0, , .	0.4	0
59	TAMI-33. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii220-ii220.	1.2	0